News >

Lead Investigator Discusses Nivolumab Long-Term Survival Benefit in SCCHN

Angelica Welch
Published: Wednesday, Apr 25, 2018

Robert L. Ferris, MD, PhD

Robert L. Ferris, MD, PhD
Updated 2-year findings from the phase III CheckMate-141 trial showed a 32% reduction in the risk of death in patients with metastatic or recurrent squamous cell carcinoma of the head and neck treated with nivolumab (Opdivo) compared with investigator’s choice of chemotherapy.

during the meeting, Ferris, who is the director of University of Pittsburgh Medical Center Hillman Cancer Center, discussed the implications of these updated findings, adding that this trial confirms the hypothesis that head and neck cancer is an immune-responsive disease.

OncLive: What were the significant findings of this 2-year update?

Ferris: The CheckMate-141 trial was a randomized phase III registrational study, which compared nivolumab with investigator's choice of chemotherapy. For a group of patients who have very poor prognosis, it was the first study to demonstrate that immunotherapy was clinically effective and better than the standard of care at the primary analysis. It was stopped early because of a positive signal at the interim data [analysis]. We are now showing, with long-term data, that the benefit persists and the OS is approximately triple of the investigator's choice of chemotherapy. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication